A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens.
Rachel ChevalierThomas Mario AttardSara L Van DriestValentina ShakhnovichPublished in: Expert opinion on drug metabolism & toxicology (2023)